サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1412560

ホジキンリンパ腫治療市場：タイプ、治療法、エンドユーザー別-2024-2030年の世界予測

Hodgkin Lymphoma Treatment Market by Type (Classical Hodgkin Lymphoma, Nodular Lymphocyte-Hodgkin Lymphoma), Treatment (Chemotherapy, Drugs, Radiation), End-User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ホジキンリンパ腫治療市場：タイプ、治療法、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ホジキンリンパ腫治療市場規模は2023年に12億1,000万米ドルと推計され、2024年には13億1,000万米ドルに達し、CAGR 9.06%で2030年には22億3,000万米ドルに達すると予測されます。

ホジキンリンパ腫治療の世界市場

主な市場の統計
基準年[2023］ 12億1,000万米ドル
予測年[2024］ 13億1,000万米ドル
予測年 [2030] 22億3,000万米ドル
CAGR（%） 9.06%
ホジキンリンパ腫治療 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはホジキンリンパ腫治療市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ホジキンリンパ腫治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-ホジキンリンパ腫治療市場の市場規模および予測は？

2-ホジキンリンパ腫治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-ホジキンリンパ腫治療市場における技術動向と規制の枠組みは？

4-ホジキンリンパ腫治療市場における主要ベンダーの市場シェアは？

5-ホジキンリンパ腫治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中でホジキンリンパ腫の発生率が増加
      • 早期発見のための高度な診断技術の存在
      • ホジキンリンパ腫に対するサージング標的療法と免疫療法
    • 抑制要因
      • ホジキンリンパ腫治療に関連する副作用
    • 機会
      • HLの新しい治療法に関する継続的な調査活動
      • ホジキンリンパ腫における新しい治療アルゴリズムのイントロダクション
    • 課題
      • ホジキンリンパ腫疾患に関する認識が限られている
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 ホジキンリンパ腫治療市場：タイプ別

  • 古典的ホジキンリンパ腫
  • 結節性リンパ球ホジキンリンパ腫

第7章 ホジキンリンパ腫治療市場治療別

  • 化学療法
  • 薬物
  • 放射線

第8章 ホジキンリンパ腫治療市場：エンドユーザー別

  • クリニック
  • 病院
  • 研究センター

第9章 南北アメリカのホジキンリンパ腫治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のホジキンリンパ腫治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのホジキンリンパ腫治療市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Actiza Pharmaceutical Private Limited
    • Baxter International Inc.
    • BIOGEN INC.
    • Bristol Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Fresenius Kabi LLC
    • LGM Pharma, LLC
    • Mayo Clinic
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
  • FIGURE 7. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CLASSICAL HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NODULAR LYMPHOCYTE-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 9. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RESEARCH CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 144. HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. HODGKIN LYMPHOMA TREATMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-742BD517F78E

[193 Pages Report] The Hodgkin Lymphoma Treatment Market size was estimated at USD 1.21 billion in 2023 and expected to reach USD 1.31 billion in 2024, at a CAGR 9.06% to reach USD 2.23 billion by 2030.

Global Hodgkin Lymphoma Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.21 billion
Estimated Year [2024] USD 1.31 billion
Forecast Year [2030] USD 2.23 billion
CAGR (%) 9.06%
Hodgkin Lymphoma Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hodgkin Lymphoma Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hodgkin Lymphoma Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include Actiza Pharmaceutical Private Limited, Baxter International Inc., BIOGEN INC., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius Kabi LLC, LGM Pharma, LLC, Mayo Clinic, Merck & Co., Inc., Novartis AG, Pfizer Inc., Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Classical Hodgkin Lymphoma
    • Nodular Lymphocyte-Hodgkin Lymphoma
  • Treatment
    • Chemotherapy
    • Drugs
    • Radiation
  • End-User
    • Clinics
    • Hospital
    • Research Center
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hodgkin Lymphoma Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hodgkin Lymphoma Treatment Market?

3. What are the technology trends and regulatory frameworks in the Hodgkin Lymphoma Treatment Market?

4. What is the market share of the leading vendors in the Hodgkin Lymphoma Treatment Market?

5. Which modes and strategic moves are suitable for entering the Hodgkin Lymphoma Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Hodgkin Lymphoma Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of hodgkin lymphoma all over the world
      • 5.1.1.2. Presence of advanced diagnostic technique for early detection
      • 5.1.1.3. Surging targeted and immunotherapy for hodgkin lymphoma
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects of hodgkin lymphoma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities for novel treatments of HL
      • 5.1.3.2. Introduction of new treatment algorithms in hodgkin lymphoma
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness about hodgkin lymphoma disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Hodgkin Lymphoma Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Classical Hodgkin Lymphoma
  • 6.3. Nodular Lymphocyte-Hodgkin Lymphoma

7. Hodgkin Lymphoma Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Drugs
  • 7.4. Radiation

8. Hodgkin Lymphoma Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospital
  • 8.4. Research Center

9. Americas Hodgkin Lymphoma Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hodgkin Lymphoma Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hodgkin Lymphoma Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Actiza Pharmaceutical Private Limited
    • 13.1.2. Baxter International Inc.
    • 13.1.3. BIOGEN INC.
    • 13.1.4. Bristol Myers Squibb Company
    • 13.1.5. Eli Lilly and Company
    • 13.1.6. F. Hoffmann-La Roche Ltd.
    • 13.1.7. Fresenius Kabi LLC
    • 13.1.8. LGM Pharma, LLC
    • 13.1.9. Mayo Clinic
    • 13.1.10. Merck & Co., Inc.
    • 13.1.11. Novartis AG
    • 13.1.12. Pfizer Inc.
    • 13.1.13. Spectrum Pharmaceuticals, Inc.
    • 13.1.14. Takeda Pharmaceutical Company Limited
    • 13.1.15. Teva Pharmaceutical Industries Ltd.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing